RET/Papillary Thyroid Cancer Rearrangement in Nonneoplastic Thyrocytes: Follicular Cells of Hashimoto’s Thyroiditis Share Low-Level Recombination Events with a Subset of Papillary Carcinoma

Rhoden, Kerry J.; Unger, Kristian; Salvatore, Giuliana; Yilmaz, Yesim; Vovk, Volodymyr; Chiappetta, Gennaro; Qumsiyeh, Mazin B.; Rothstein, Jay L.; Fusco, Alfredo; Santoro, Massimo; Zitzelsberger, Horst; Tallini, Giovanni

doi:10.1210/jc.2006-0240

Cited by 175 publications

(146 citation statements)

References 28 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…Initial reports suggested that RET/PTC was specific for PTC [183,184] but later it was also found in some benign lesions [185,186] and diseases such as Hashimato disease [187]. According to these results, RET/PTC is not a specific PTC marker.…”

Section: Molecular Targets In Histopathological Diagnosis and Classifmentioning

confidence: 99%

An update on molecular biology of thyroid cancers

Ömür

Baran

2014

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: Molecular Targets In Histopathological Diagnosis and Classifmentioning

confidence: 99%

An update on molecular biology of thyroid cancers

Ömür

Baran

2014

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…The incidence of RET/PTC in radiation-induced childhood PTCs is in the range of 50-70% (Klugbauer et al, 1995;Smida et al, 1999;Thomas et al, 1999;Rabes et al, 2000), whereas in sporadic papillary carcinomas in adults the incidence is somewhat lower (5-30%) (Jhiang and Mazzaferri, 1994). However, the identification of RET/PTC in other common thyroid tumour histotypes such as oncocytic adenomas and carcinomas (Cheung et al, 2000), and even in hyperplastic thyroid nodules (Ishizaka et al, 1991;Elisei et al, 2001) and Hashimoto's thyroiditis (Rhoden et al, 2006), seems to challenge the validity of RET/PTC as a tumour marker and its specificity for PTC. Moreover, it has been recently shown that the level of RET/PTC expression in papillary carcinoma is highly variable, suggesting that the distribution of RET/PTC within one tumour may not be homogenous (Rhoden et al, 2004;Unger et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC

et al. 2008

View full text Add to dashboard Cite

The aim of this study is to investigate additional genetic alterations in papillary thyroid carcinomas (PTCs) with known RET/PTC rearrangements. We applied arraybased comparative genomic hybridization (array CGH) to 33 PTC (20 PTC from adults, 13 post-Chernobyl PTC from children) with known RET/PTC status. Principal component analysis and hierarchical cluster analysis identified cases with similar aberration patterns. Significant deviations between tumour-groups were obtained by statistical testing (Fisher's exact test in combination with Benjamini-Hochberg FDR-controlling procedure). FISH analysis on FFPE sections was applied to validate the array CGH data. Deletions were found more frequently in RET/PTC-positive and RET/PTC-negative tumours than amplifications. Specific aberration signatures were identified that discriminated between RET/PTC-positive and RET/PTC-negative cases (aberrations on chromosomes 1p, 3q, 4p, 7p, 9p/q, 10q, 12q, 13q and 21q). In addition, childhood and adult RET/PTC-positive cases differ significantly for a deletion on the distal part of chromosome 1p. There are additional alterations in RET/PTC-positive tumours, which may act as modifiers of RET activation. In contrast, alterations in RET/ PTC-negative tumours indicate alternative routes of tumour development. The data presented serve as a starting point for further studies on gene expression and function of genes identified in this study.

show abstract

“…Rhoden and colleagues reported that only few follicular cells, expressing very low levels of RET/PTC, were detected in Hashimoto's thyroiditis, thus suggesting that RET/PTC expression does not necessarily predicts the development of a PTC in patients with thyroiditis [63].…”

Section: Genetic Alterationsmentioning

confidence: 99%

Thyroid Autoimmunity and Cancer

Felicetti¹,

Catalano²,

Fortunati³

2017

Endocrine Immunology

View full text Add to dashboard Cite

Cancer and autoimmune diseases are often associated in the same individual. The functional link between immune system and cancer development is only partially known. Even though the immune system can control the development of cancer through immune surveillance, cancer cell itself can escape immune surveillance. Actually, it is debated whether autoimmune diseases have to be regarded as cancer cause or its consequence.In particular, autoimmune thyroiditis and thyroid cancer (in particular, papillary thyroid cancer) are a fascinating model of this complex relationship. In the present review, we describe what has been reported by now in literature about autoimmune thyroiditis and papillary thyroid cancer, and on the basis of available data, we try to clarify the present knowledge.

show abstract

RET/Papillary Thyroid Cancer Rearrangement in Nonneoplastic Thyrocytes: Follicular Cells of Hashimoto’s Thyroiditis Share Low-Level Recombination Events with a Subset of Papillary Carcinoma

Cited by 175 publications

References 28 publications

An update on molecular biology of thyroid cancers

An update on molecular biology of thyroid cancers

Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC

Thyroid Autoimmunity and Cancer

Contact Info

Product

Resources

About